steven tepper pharmaceut biom analyst
review rais tp in-line result despit
result expect still rel strong
quarter lift toward high end compani guidanc last
revenu adjust ep in-line
expect market respect
number help integr recent acquir oral hygien product
maker ranir also healthi growth organ sale result new product
launch high season demand allergi cold medicin
believ core busi show initi sign
recoveri re-establish consist growth organ sale
percol bottom line well take time result
strateg plan manag introduc turn perform around
therefor take time deliv long last meaning
announc guidanc adjust ep forecast
rang consider lower market forecast
although compani guid revenu growth
realli reflect correspond ep growth stand
analysi forecast growth ep come entireti compani new
issu flag earn call color around contribut made
cost effici drive project momentum organ growth new
launch question ask turn around compani infant
formula busi contribut two new oral hygien asset perrigo
ad sinc acquir ranir steripod high ridg issu rais
contribut launch high margin gener version
proair inhal also clarif whether rx segment
culprit respons weak profit
manag answer virtual question essenti perrigo
prefer keep guidanc conserv ceo kessler confirm
compani spend extra million cost next year help drive
busi forward kessler went say aim deliv sustain
profit growth long term
consum self america csca revenu grew yoy
estim sale growth core busi discount
contribut ranir divest anim health busi
impress
manag claim growth organ sale reach calcul factor
contribut strong season growth sale allergi cold medicin
growth over-the-counter product sale particular share privat label product
market also robust growth on-line sale adjust oper margin slightli higher
profit product mix improv perform infant
formula busi lower api cost partial off-set higher labor cost
increas spend
consum self intern csci revenu grew yoy
calcul organ sale segment strip contribut ranir
fx headwind grew new product launch adjust oper
margin slightli higher result integr ranir improv
perform compani uk busi
rx revenu increas yoy new launch growth sale
volum slippag adjust oper margin narrow yoy
result price pressur gener loss exclus compani
testosteron base gel extra spend compani made cours
secur approv gener version proair inhal
set busi year come new launch includ
two major product infant formula busi gener proair inhal
consider number smaller launch compani unwil disclos
stage competit reason
valuat outlook
maintain market perform rate adjust price target
compani ceo make good promis made
appoint around year ago refocu compani core consum product busi
rebrand self care rather healthcar compani expect transit
long process think take quarter see resumpt
growth top bottom line accordingli process see compani
implement cost effici develop footprint new product categori
person self-car space
revis valuat impli multipl eps believ
leadership consum healthcar product space deserv
premium valuat multipl higher gener rival high
consum product conglomer stabl mega brand compani still
need demonstr growth driver place divest rx busi
continu weigh compani underli perform
-for qualifi client
